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nsights From RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam
ardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology
ospital) Registries
oshinobu Onuma, MD,* Chrysafios Girasis, MD,* Nicolo Piazza, MD,*
ector M. Garcia-Garcia, MD,* Neville Kukreja, MA,* Scot Garg, MD,*
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on van Domburg, PHD,* Patrick W. Serruys, MD, PHD,* on behalf of Interventional
ardiologists at Thoraxcenter 2000–2005
otterdam, the Netherlands; and Ferrara, Italy
bjectives We investigated the long-term clinical outcomes and independent predictors of major
ardiac events in unprotected left main coronary artery disease (ULMCA) patients treated by percu-
aneous coronary intervention with drug-eluting stent (DES).
ackground There is limited information on long-term (3 years) outcomes after DES implantation
or ULMCA. Furthermore, bifurcation angle and SYNTAX (Synergy between Percutaneous Coronary
ntervention with Taxus and Cardiac Surgery) score are emerging as parameters for patient risk strat-
ﬁcation, and their prognostic implications have still to be elucidated.
ethods One hundred forty-eight patients with ULMCA treated with DES were analyzed and com-
ared with a historical cohort of 79 patients who received bare-metal stents for the treatment of
LMCA. Patient-oriented composite end point was deﬁned as the occurrence of all-cause death, any
yocardial infarction, or any revascularization.
esults The 4-year cumulative incidence of all-cause death, any myocardial infarction, any revascular-
zation, and patient-oriented composite were 35.6%, 3.8%, 25.2%, and 54.4%, respectively. These end
oints had relatively increased from 1 year to 4 years by ∆70%, ∆5%, ∆50%, and ∆68%, respectively.
hen compared with a historical cohort who received bare-metal stents for ULMCA treatment, landmark
nalysis performed after the ﬁrst 2 years of follow-up demonstrated that the DES cohort had signiﬁ-
antly higher patient-oriented composite end point over the last 2 years of follow-up (26% vs. 8%,
 0.02). EuroSCORE (European System for Cardiac Operative Risk Evaluation), cardiogenic shock,
nd SYNTAX score were identiﬁed as independent predictors for the 4-year patient-oriented com-
osite, whereas bifurcation angle was not.
onclusions Late increase in patient-oriented composite end points after DES implantation for ULMCA
arrants careful and long-term follow-up. SYNTAX score and EuroSCORE appear to have a signiﬁcant
rognostic value in long-term patient risk. (J Am Coll Cardiol Intv 2010;3:584–94) © 2010 by the
merican College of Cardiology Foundation
rom the *Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; and †The Cardiovascular Institute, University of
errara, Ferrara, Italy.anuscript received February 11, 2010, accepted March 4, 2010.
T
n
C
m
c
t
(
w
p
l
c
w
a
d
b
t
h
o
i
y
q
p
s
S
E
b
a
r
p
c
s
C
(
s
o
c
L
a
e
o
t
M
S
a
w
h
r
i
t
r
i
S
(
r
t
p
d
l
h
t
P
r
m
s
i
i
e
w
c
s
t
c
t
t
t
d
d
r
w
s
p
p
i
Q
f
a
c
r
t
w
p
s
I
w
c
d
s
t
N
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 6 , 2 0 1 0 Onuma et al.
J U N E 2 0 1 0 : 5 8 4 – 9 4 Long-Term Outcome After LM Stenting
585he prevalence of left main disease in patients with coro-
ary artery atherosclerosis varies from 2.5% to 10% (1).
oronary artery bypass graft (CABG) remains the treat-
ent of choice in patients with unprotected left main
oronary artery disease (ULMCA) (2,3). Although percu-
aneous coronary intervention (PCI) using bare-metal stent
BMS) in patients having 2- or 3-vessel disease is associated
ith no significant difference in long-term mortality com-
ared with CABG, restenosis and need for repeat revascu-
arization remain major limitations of this mode of revas-
See page 642
ularization. These latter limitations have precluded the
idespread use of PCI, not only in multivessel disease, but
lso in LM disease (4). Reduction of restenosis with
rug-eluting stents (DES), however, has raised the possi-
ility of their use for multivessel treatment as well as LM
reatment. So far, several registries and randomized trials
ave investigated the short- and mid-term clinical outcomes
f PCI using DES for ULMCA treatment (5–14), but little
s known about its long-term safety and efficacy beyond 3
ears (15). In addition, the rate of potentially fatal conse-
uences of stent thrombosis or in-stent restenosis in this
atient subset has not fully been investigated (16,17).
Several clinical and angiographic parameters for risk
tratification after PCI are emerging. Recently, Euro-
CORE (European System for Cardiac Operative Risk
valuation), a typically surgical risk stratification score, has
een applied to the PCI population (18). As angiographic
nalysis, the angle between bifurcated branches has been
ecognized as a significant prognostic factor for immediate
rocedural outcomes as well as for intermediate-term out-
omes (19–21). In addition, a comprehensive, angiographic
coring system, the SYNTAX (Synergy between Percutaneous
oronary Intervention with Taxus and Cardiac Surgery) score
22,23) based on morphology and location of coronary artery
tenoses in the coronary tree has been proven to predict clinical
utcomes in high-risk patients (9,24,25).
The main aim of this study was to report the long-term
linical outcomes of patients receiving DES for unprotected
M lesions in a daily practice of a tertiary medical center. In
ddition, we assessed the prognostic value of recently
merging predictors of adverse outcomes for PCI treatment
f multivessel disease and ULMCA, such as EuroSCORE,
he bifurcation angle, and SYNTAX score.
ethods
tudy design and patient population. Between April 2002
nd December 31, 2005, 210 consecutive patients under-
ent PCI for LM stenting (7,8). Sixty-two patients with a
istory of CABG were not retained in this analysis. The
emaining 148 patients are the subject of the present pnvestigation. On April 16, 2002, our institution adopted
he use of sirolimus-eluting stents (Cypher, Cordis, War-
en, New Jersey) as the default strategy for all coronary
nterventions, as part of RESEARCH (Rapamycin-Eluting
tent Evaluated at Rotterdam Cardiology Hospital) registry
26). On February 16, 2003, sirolimus-eluting stents were
eplaced by paclitaxel-eluting stents (Taxus Express2, Bos-
on Scientific, Natick, Massachusetts) as the default stent, as
art of the T-SEARCH (Taxus-Stent Evaluated at Rotter-
am Cardiology Hospital) registry (27). For evaluation of
ong-term outcomes, this DES group was compared with a
istorical cohort who received BMS in the unprotected LM
runk before April 2002 (n  79).
In this study, the decision to intervene in the patients with
CI was based on a consensus
eached during a multidisciplinary
edical surgical conference (the
o-called heart-team conference)
nvolving surgeon, interventional-
st, and referring physician (28),
xcept for patients who presented
ith ST-segment elevation myo-
ardial infarction (STEMI), con-
idering the emergent character of
he clinical presentation. All pro-
edures were performed according
o standard clinical guidelines at
he time. All patients were pre-
reated with 300 mg of clopi-
ogrel. At least 1 month of clopi-
ogrel treatment (75 mg/day) was
ecommended for patients treated
ith BMS. Clopidogrel was pre-
cribed for at least 3 months for
atients with DES. Life-long as-
irin therapy was recommended
n all patients.
CA analysis. To assess the bi-
urcation angle between the left
nterior descending and left cir-
umflex arteries, 3-dimensional quantitative coronary angiog-
aphy (QCA) analyses were performed by 2 observers blinded
o the patient data and clinical outcomes. A validated program
as used to reconstruct 3-dimensional images from 2 different
rojections at least 30° apart from each other (CardiOp-B
ystem version 2.1.0.151, Paieon Medical Ltd., Park Afek,
srael) (29–31). Separate 3-dimensional angiographic images
ere constructed for systolic and diastolic phases. The bifur-
ation angle was defined as the angle between the left anterior
escending and left circumflex arteries (32). In cases where the
eparate projections were not available, 2-dimensional bifurca-
ion software (CAAS version 5.6, PieMedical, Maastricht, the
etherlands) was used to calculate bifurcation angle (33). In
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
LM  left main
MACCE  major adverse
cerebrovascular cardiac
event
MACE  major adverse
cardiac events
PCI  percutaneous
coronary intervention
QCA  quantitative coronary
angiography
STEMI  ST-segment
elevation myocardial
infarction
TVR  target vessel
revascularization
ULMCA  unprotected left
main coronary artery diseaserimary PCI cases where TIMI (Thrombolysis In Myocardial
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586nfarction) flow grade was 0 or 1 pre-procedure, the cinean-
iography following the first balloon angioplasty was analyzed
or the determination of the angle.
YNTAX score. Two analysts blinded to patient characteris-
ics and clinical outcomes reviewed the angiograms to
alculate the SYNTAX score (22,23). In case of disagree-
ent, the opinion of a third observer was obtained and the
nal decision was made by consensus. Each coronary lesion
roducing 50% luminal obstruction in vessels 1.5 mm
as separately scored and added to provide the overall
YNTAX score. The SYNTAX score was calculated using
edicated software that integrates the following: 1) the
umber of lesions with their specific weighting factors based
n the amount of myocardium distal to the lesion according
o the score of Leaman et al. (34); and 2) the morphologic
eatures of each single lesion (35,36). The reproducibility of
he SYNTAX score was recently reported (22).
linical follow-up. Survival data for all patients were ob-
ained from municipal civil registries on a yearly basis. A
uestionnaire was subsequently sent to all living patients
ith specific enquiries on rehospitalization and major ad-
erse cardiac events (MACE). As the principal regional
ardiac referral center, most repeat revascularization (either
ercutaneous or surgical) is normally performed at our
nstitution and recorded prospectively in our database. For
atients who suffered an adverse event at another center,
edical records or discharge letters from the other institu-
ions were systematically reviewed. General practitioners
nd referring physicians were contacted for additional in-
ormation if necessary. Causes of death were obtained from
edical records when they happened during hospitalization,
nd otherwise from the Central Bureau of Statistics, The
ague, the Netherlands (37,38). Causes of death were
lassified according to the International Classification of
iseases and Related Health Problems-10th Revision. For
he present analysis, death from ischemic heart disease (I-20
o I-25), sudden cardiac death (I-46), sudden death unde-
ned (R-96), or death from heart failure (I-50) were
onsidered to be cardiac. Death from cancer was defined as
ny death from malignant neoplasm (C-009 to C-97). All
he remaining deaths were classified as being due to other
auses, and no further distinction was made. In this study,
here was no mandatory angiographic follow-up.
nd point deﬁnitions. The primary end point was a patient-
riented composite defined as all-cause death or any myo-
ardial infarction (MI) or any revascularization (all surgical
nd percutaneous, target lesion, target vessel, and non–
arget vessel revascularization) according to the Academic
esearch Consortium definitions (39). The secondary end
oint was the device-oriented composite end point defined as
ardiac death,MI in the target vessel territory, or a target lesion
evascularization. In addition, each individual component end
oint was analyzed in a nonhierarchical way. Definite stent phrombosis was also considered as a separate secondary end
oint.
Myocardial infarction included periprocedural MI (diag-
osed by a rise in creatine kinase-myocardial band fraction
f 3 times the upper limit of normal), reinfarction (defined
s recurrence of symptoms together with ST-segment ele-
ation or new left bundle branch block and an increase in
ardiac enzymes following stable or decreasing values), or
pontaneous MI (diagnosed by any rise in creatine kinase-
yocardial band fraction above the upper limit of normal)
40). Target lesion revascularization was defined as a repeat
evascularization of in-stent or within 5 mm proximal or
istal to the stent implanted in the index procedure (41).
arget vessel revascularization (TVR) was defined as any
evascularization in the same epicardial vessel treated in the
ndex procedure. Definite stent thrombosis was defined as
IMI flow grade 0 or 1 or the presence of a flow-limiting
hrombus, accompanied by acute symptoms, irrespective of
hether there had been an intervening reintervention (42).
he timing of stent thrombosis was categorized as early
within 30 days after implantation), late (between 30 days
nd 1 year), or very late (more than 1 year) (39).
tatistical analysis. Continuous variables are presented as
ean  SD, whereas categorical variables are expressed as
ercentages. Comparisons among groups were performed by
he independent t test for continuous variables and Pearson
hi-square test for categorical variables. All statistical tests were
-tailed, and p value of 0.05 was considered as statistically
ignificant. The incidence of events over time was studied with
he use of the Kaplan-Meier method, whereas log-rank tests
ere applied to evaluate differences between the current cohort
nd the historical control. Patients lost to follow-up were
onsidered at risk until the date of last contact, at which point
hey were censored. Cox regression models were built to
lucidate independent predictors of clinical end points. Signif-
cant variables in univariate analysis (p  0.1) were selected to
ut in the multivariate model. The following pre-procedural
ariables were included in the initial univariate analysis: gender,
iabetes, current smoking habit, hypertension, hypercholester-
lemia, age, previous history of myocardial infarction or PCI,
YNTAX score, EuroSCORE, shock at entry, clinical pre-
entation, and bifurcation angle. Clinical presentation
STEMI, unstable angina or non-STEMI, and stable angina)
as coded as a categorical variable. Bifurcation angle was
artitioned according to tertiles (lowest tertile as a reference).
he results are presented as adjusted hazard ratios (HR) with
5% confidence intervals (CI). Statistical analysis was per-
ormed with SPSS version 16 for windows (SPSS Inc.,
hicago, Illinois).
esults
aseline and procedural characteristics. The baseline and
rocedural characteristics of the patients are shown in Table 1.
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587he mean age of the patients was 64.9 years old, 16.2% of
he patients had diabetes, and 33% had previous history of
I. Approximately one-quarter of patients presented with
TEMI, and 8% presented with severe hemodynamic com-
romise at entry. The average additive EuroSCORE and
YNTAX score was 4.26 and 39.4, respectively.
linical outcomes. Clinical follow-up was available in all
atients, with a median duration of follow-up of 1,473 days
Table 1. Baseline Characteristics
Curren
Demographics
Age, yrs
Men
Diabetes
Hypertension
Hypercholesterolemia
Family history of coronary artery disease
Current smoking
Previous PCI
Previous MI
Additive EuroSCORE
SYNTAX score
LVEF, %
Presentation
STEMI
Stable angina
Unstable angina/non-STEMI
Shock at entry
Pre-procedural quantitative angiographic analysis
Bifurcation angle in diastole, °
Bifurcation angle in systole, °
Minimal lumen diameter, mm
Reference vessel diameter, mm
Procedural characteristics
Number of implanted stents
Total stented length per patient
Average stent diameter
Clopidogrel duration in month
IVUS use
Stenting strategy
Provisional
Culotte
T-stenting
Crush stenting
Kissing technique
Post-procedural bifurcation angle
Bifurcation angle in diastole, °
Bifurcation angle in systole, °
Values are expressed as n (%) or mean SD.
BMS bare-metal stents; DES drug-eluting stents; EuroSCORE
ultrasound; LVEF left ventricular ejection fraction; MImyocardial
elevation myocardial infarction; SYNTAX Synergy Between Percutaninterquartile range: 1,182 to 1,848 days) for patients alive at sollow-up. Hierarchical count of adverse events is shown in
able 2. Patient-oriented composite increases from 32.4%
t 1 year to 51.4% at 4 years (58%), which was mainly driven
y an increase in all-cause mortality from 19.6% at 1 year to
3.1% at 4 years, a relative increase of 68%. There was 1 case
f definite late stent thrombosis at 1 year, and there was 1 case
f definite very late stent thrombosis at 4 years.
Kaplan-Meier estimates of clinical end points are pre-
ort With DES
148)
Historical Cohort With BMS
(n  79) p Value
12.1 65.1 11.2 0.96
(73) 49 (62) 0.10
16.2) 15 (19) 0.59
41) 34 (43) 0.89
54) 34 (43) 0.13
32) 15 (19) 0.04
18) 14 (18) 1.00
22) 25 (32) 0.11
33) 24 (30) 0.77
3.54 4.37 3.57 0.82
22.9 36.8 24.6 0.96
13.6 41.8 16.9 0.48
24.3) 22 (27.8) 0.64
40.5) 30 (33.3) 0.78
35.1) 27 (34.2) 1.00
8.8) 6 (7.6) 1.00
25.5 89.5 25.3 0.29
26.6 81.42 23.8 0.42
0.32 1.08 0.27 0.92
2.49 3.31 0.36 0.69
0.37 2.85 0.47 0.0001
40.4 42.4 28.4 0.0001
0.37 3.52 0.47 0.0001
5.32 5.27 4.86 0.01
32) 34 (43) 0.15
77) 70 (89) 0.07
9) 1 (1)
10) 8 (10)
3) 0
1) 0
24.8 84.2 25.9 0.83
23.7 76.7 21.2 0.38
an System for Cardiac Operative Risk Evaluation; IVUS intravascular
on; PCI percutaneous coronary intervention; STEMI ST-segment
oronary Intervention with Taxus and Cardiac Surgery.t Coh
(n 
64.9
108
24 (
61 (
80 (
47 (
27 (
32 (
49 (
4.26
39.4
45.3
36 (
60 (
52 (
13 (
94.1
84.9
1.09
3.35
3.08
59.9
3.08
7.53
48 (
114 (
13 (
15 (
4 (
2 (
85.1
80.0
Europe
infarctiented in Figures 1A to 1C. At 4 years, the cumulative
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588ncidence of all-cause death, MI, any revascularization, and
atient-oriented composite were 35.6% (95% CI: 27.3% to
3.8%), 3.8% (95% CI: 0.5% to 7.1%), 25.2% (95% CI:
6.9% to 33.6%), and 54.4% (95% CI: 45.8% to 63.1%),
espectively. Cardiac mortality, all-cause mortality, and any
evascularization rate relatively increased from 1 year to 4
ears by 68%, 82%, and 49%, respectively, whereas the
hanges in target lesion revascularization and MI was less
ncreased from 1 year to 4 years (5% and 28%, respec-
ively) (Figs. 1A and 1B). In summary, the device-oriented
nd patient-oriented composite increased from 1 year to 4
ears by 56% and 68%, respectively (Fig. 1C). If strati-
ed by the presentation with STEMI versus others (non-
TEMI, unstable angina, and stable angina), the patient-
riented composite was higher in STEMI patients (68.6%)
han the others (49%, p  0.001), also the device-oriented
omposite, all-cause death, and cardiac death were higher in
he STEMI patients than the others (53% vs. 30%, p 0001;
5% vs. 29%, p  0.001; 48% vs. 16%, p  0.001) (Fig. 2A).
ith stratification according to the tertiles of EuroSCORE
2, 2 and 5, 5), the patient-oriented composite was
igher in the high tertile (76.8%) than in the low (41.2%,
og-rank p  0.001) or intermediate tertiles (51.8%, log-rank
 0.001) (Fig. 2B). If stratified according to type of DES
Table 2. Hierarchical Count of Patient-Oriented Composite After
DES Implantation Compared With the Historical Cohort With BMS
Current Cohort
With DES
(n  148)
Historical Cohort
With BMS
(n  79) p Value
1 yr
All-cause death 29 (19.6) 23 (29.1) 0.14
Any MI 2 (1.4) 1 (1.3) 1.00
Any revascularization 17 (11.5) 10 (12.7) 1.00
Patient-oriented composite 48 (32.4) 34 (43) 0.15
2 yrs
All-cause death 35 (23.6) 27 (34.2) 0.11
Any MI 3 (2.0) 1 (1.3) 1.00
Any revascularization 19 (12.8) 11 (13.9) 0.84
Patient-oriented composite 57 (38.5) 39 (49.4) 0.12
3 yrs
All-cause death 41 (27.7) 29 (36.7) 0.18
Any MI 3 (2.0) 1 (1.3) 1.00
Any revascularization 23 (15.5) 11 (13.9) 0.85
Patient-oriented composite 67 (45.3) 41 (51.9) 0.4
4 yrs
All-cause death 49 (33.1) 30 (38) 0.47
Any MI 3 (2.0) 1 (1.3) 1.00
Any revascularization 24 (16.2) 11 (13.9) 0.7
Patient-oriented composite 76 (51.4) 42 (53.2) 0.9
Event rates were calculated as number of events divided by total number of patients and
therefore differ from those in the figures, where event rates were calculated by Kaplan-Meier
methods. In this table, comparison was made with the chi-square or Fisher exact test.
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Figure 1. Kaplan-Meier Estimates After Implantation of DES
(A) Kaplan-Meier estimates demonstrate all-cause mortality (black line) and
cardiac mortality (red line). (B) Kaplan-Meier estimates present the end points
of any myocardial infarction (red line), target lesion revascularization (blue
line), target vessel revascularization (green), and any revascularization includ-
ing target and non–target vessel revascularization (black line). (C) Kaplan-
Meier estimates show the composite end point (red line) of cardiac mortality,
myocardial infarction in the stented vessel territory, or target lesion revascular-
ization and the composite end point (black line) of all-cause mortality, any
myocardial infarction, or any revascularization. DES  drug-eluting stent.
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589Figure 2. Kaplan-Meier Estimates After Implantation of DES With Stratification of Subgroups
(A) All-cause mortality and (B) patient-oriented composite end point (all-cause mortality, any myocardial infarction [MI]), or any revascularization) according to a
presentation of ST-segment elevation myocardial infarction or the others (stable angina, non–ST-segment elevation myocardial infarction, or unstable angina).
Patient-oriented composite end point stratiﬁed by (C) tertile division of EuroSCORE (European System for Cardiac Operative Risk Evaluation) with cutoff values of
2 and 5 and (D) tertiles of SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score of the current cohort (cutoff
values of 27 and 44). (E) The patient-oriented composite end points were classiﬁed according to tertiles of bifurcation angle (BA) between the left anterior
descending and circumﬂex arteries (cutoff values of 67 and 91.7). Abbreviations as in Figure 1.
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5903.8% in Cypher and 54.8% in paclitaxel-eluting stent (p 
.83), whereas the all-cause mortality was 30.8% versus 36.5%,
espectively (p  0.56).
omparison with historical cohort. Patient demographics in
he historical control (n  79) were similar to the current
ohort except for a lower frequency of family history of
oronary artery disease (32% vs. 19%, p 0.04), reflecting that
he changes in clinical practice, number of implanted stents,
tent length, stent diameter, and clopidogrel duration are
igher in the current cohort than in the historical control
roup.
Figure 3 shows the Kaplan-Meier estimates of all-cause
ortality and the patient-oriented composite end point of
he current cohort with DES and the historical control with
MS. At 1 year, the rate of all-cause death (current cohort
9.6% vs. historical cohort 29.1%) and patient-oriented
omposite (32.4% vs. 43.0%) was lower in the current
ohort than in the historical cohort (Figs. 3A and 3B). At 4
ears the events rate, however, became comparable between
he 2 groups (all-cause mortality: 38.0 vs. 35.6%, p  0.48;
atient-oriented composite: 54.4 vs. 53.2%, p  0.64) as a
esult from a late increase of events in the current cohort.
aplan-Meier estimate before 2 years yielded a numerically
igher patient-oriented composite end point in the histor-
cal cohort (log-rank p  0.1), whereas landmark analysis
Fig. 3B) after the second year demonstrated a significantly
igher event rate in the current cohort than the historical
ohort (log-rank p  0.02).
YNTAX score. In the current cohort, the SYNTAX score
anged from 7 to 104 with median of 33.0. If the SYNTAX
core is divided into tertiles, the cutoff values were 27.0 and
4.0. The Kaplan-Meier curves of device-oriented compos-
te stratified by these tertiles of SYNTAX score are presented
n Figure 2C. The 4-year event rates were 46.2%, 55.1%, and
9.6% in low, intermediate, and high tertile groups, respec-
ively. High tertile group demonstrated significantly higher
vent rates than intermediate tertile (log-rank p  0.03) and
ow tertile (log-rank p  0.005) groups did.
hree-dimensional QCA analysis. Three-dimensional QCA
nalysis was feasible in only 50.7% of patients due to the
navailability of 2 separate angiographic views of more than
0° that is a prerequisite for 3-dimensional QCA; in the
emaining patients, 2-dimensional QCA was performed.
he results are shown in Table 1. In the patient receiving
ES, the Kaplan-Meier curves of patient-oriented compos-
te were separated according to the tertiles of systolic
ifurcation angle (high 91.7, intermediate 91.7 and
67, low 67) as shown in Figure 2E. High tertile group
emonstrated higher patient-oriented composite at 4 years
66.3%) than the intermediate (51.0%) and the low (45.2%)
roups did (log-rank high vs. low: p  0.04; high vs.
ntermediate: p  0.09).
redictor of adverse events. Table 3 shows the results of the
nivariate and multivariate analyses to identify the predic- iors for all-cause mortality and for patient-oriented com-
osite. Bifurcation angle did not remain as a significant
redictor of either all-cause mortality or patient-oriented
nd point in the multivariate analysis.
At 1 year, multivariate analysis demonstrated that Euro-
CORE, age, shock at entry, and SYNTAX score were
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Figure 3. Kaplan-Meier Estimates of DES and BMS Cohorts
Kaplan-Meier estimates of the current cohort treated with drug-eluting
stent (red line) or historical cohort treated with bare-metal stent (black
line). All-cause mortality is demonstrated in (A), whereas (B) demonstrates
patient-oriented composite end point (all-cause mortality, any myocardial
infarction, or any revascularization) with a landmark analysis more than 2
years after implantation. Dotted lines  95% conﬁdence interval. BMS 
bare-metal stent(s); other abbreviations as in Figure 1.ndependent predictors for all-cause mortality and patient-
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591riented composite. At 4 years, in the final multivariate
odels, age, shock at entry, the SYNTAX score and
uroSCORE remained as independent predictors for all-
ause mortality, whereas EuroSCORE, shock at entry, and
YNTAX score were identified as independent predictors
or patient-oriented composite.
iscussion
he main findings of the current study are the following:
) At 4-year follow-up after DES implantation in
LMCA, patient-oriented composite end point was 51.4%
ith a 58% relative increase of events from 1 year to 4 years.
) A landmark analysis of the last 2 years of follow-up
ndicated a higher composite end point for the current
ohort with DES when compared with the historical cohort
ith BMS (25% vs. 8%, p  0.02). 3) EuroSCORE and
YNTAX score were independent predictors for both
ll-cause mortality and the patient-oriented composite end
oint up to 4 years, whereas pre-procedural bifurcation
ngle between the left circumflex and left anterior descend-
ng arteries was not.
According to the current guidelines of the European
ociety of Cardiology and the American Heart Association
nd American College of Cardiology guidelines (40,43), the
resence of a stenosis in the LMCA is a class IIB or III
ndication for PCI unless the patient is not eligible for
ABG in presence of extreme comorbidities and STEMI.
n the recent U.S. criteria for appropriateness of revas-
Table 3. Univariate and Multivariate Analysis for Predictors of All-Cause M
in the Left Main Trunk
All-Cause Mortality
Univariate
Hazard Ratio (95% CI) p Value
Multivariate
Hazard Ratio (95%
1-year outcome
EuroSCORE 1.26 (1.17–1.36) 0.001 1.24 (1.11–1.39)
Presentation of STEMI* 6.77 (3.56–18.66) 0.001
Age 1.06 (1.02–1.09) 0.003 1.05 (1.01–1.10)
Shock at entry 8.56 (3.83–19.1) 0.001 4.21 (1.50–1.82)
SYNTAX score† 1.35 (1.17–1.56) 0.001 1.23 (1.06–1.42)
Hypercholesterolemia 0.33 (0.15–0.73) 0.006
Hypertension 0.41 (0.18–0.96) 0.04 0.34 (0.13–0.88)
4-year outcome
EuroSCORE 1.19 (1.12–1.26) 0.001 1.13 (1.03–1.24)
Presentation of STEMI* 4.38 (2.08–9.23) 0.001
Age 1.05 (1.03–1.08) 0.001 1.04 (1.01–1.08)
Shock at entry 8.26 (4.09–16.68) 0.001 5.46 (2.35–12.69
SYNTAX score† 1.27 (1.13–1.42) 0.001 1.15 (1.02–1.30)
High bifurcation angle‡
Univariate or multivariate hazard ratios were calculated by Cox regression models.
*Stable angina used as a reference. †Each 10-point increase of SYNTAX score. ‡Low tertile bifurcat
Abbreviations as in Table 1.ularization, percutaneous treatment of LM disease is aonsidered “inappropriate” (2). In European daily prac-
ice, however, 4.6% of patients treated in the catheter-
zation lab have LM stenosis, and 58% of those are
reated by percutaneous means (44).
Up to now, 2 randomized trials have been performed to
ompare CABG and PCI using DES in patients undergo-
ng treatment for LM disease. In the LE MANS (Left
ain Coronary Artery Stenting) study by Buszman et al. (10),
CI was associated with a lower 30-day risk of major
dverse cerebrovascular cardiac event (MACCE) (p 0.03)
nd had comparable 1-year mortality or MACCE to sur-
ery. In the more recent SYNTAX trial (9), which random-
zed 1,800 patients with 3-vessel or LM coronary artery
isease to either CABG or PCI, the use of PCI at 1 year was
ssociated with safety end points (death, cerebrovascular
ccident, and MI) but a higher rate of MACCE than
ABG, due to a significantly higher rate of revasculariza-
ion. However, in the subgroup of patients with LM disease
ith an average SYNTAX score of 28.1, PCI and CABG
ere associated with similar MACCE rates at 1 year (PCI
5.8% vs. CABG 13.6%). In the DES cohort of the present
tudy, the 1-year all-cause mortality and revascularization
ate of patients treated with DES (19.6% and 16.9%,
espectively) were higher than rates reported in the LM
ubgroup of the randomized cohort in the SYNTAX trial
4.2% and 12.0%, respectively). This is likely due to the
igh-risk nature of our all-comers registry (e.g., including
4% STEMI patients with a mean EuroSCORE of 4.26
y and Patient-Oriented Composite After DES Implantation
Patient-Oriented Composite
p Value
Univariate
Hazard Ratio (95% CI) p Value
Multivariate
Hazard Ratio (95% CI) p Value
0.001 1.19 (1.12–1.26) 0.001 1.13 (1.03–1.24) 0.009
4.38 (2.08–9.23) 0.001
0.03 1.05 (1.03–1.08) 0.001 1.04 (1.01–1.08) 0.009
0.006 8.26 (4.09–16.68) 0.001 5.46 (2.35–12.69) 0.001
0.006 1.27 (1.13–1.42) 0.001 1.15 (1.02–1.30) 0.03
0.43 (0.24–0.76) 0.004
0.03 0.45 (0.24–0.84) 0.01
0.009 1.16 (1.09–1.24) 0.001 1.09 (1.02–1.16) 0.02
3.42 (1.69–6.94) 0.001
0.009 1.04 (1.01–1.070) 0.004
0.001 4.61 (2.21–6.61) 0.001 2.74 (1.30–5.80) 0.008
0.03 1.22 (1.08–1.38) 0.001 1.12 (1.01–1.24) 0.4
1.99 (0.93–4.26) 0.075
le used as a reference.ortalit
CI)
)
ion angnd an average SYNTAX score of 39.4).
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592In this analysis, we selected a patient-oriented composite
nd point as a primary end point, because it represents the
ost critical clinical approach for a population undergoing
new form of treatment. The Academic Research Consor-
ium defined 2 methodological approaches to report clinical
ollow-up: 1) the device-oriented composite end point; and
) the patient-oriented composite end point. The device-
riented approach put the accent on the efficiency and
fficacy of a new device, therefore, focusing on the cardiac
eath, MI, and reintervention related to the device. The
atient-oriented end point is a follow-up, which specifically
onsiders the welfare of the patient, and includes all-cause
eath, any MI, and any revascularization.
In the current analysis, we entered only the pre-
rocedural parameters in the multivariate analysis and ex-
luded the procedural variables such as angulation after
tenting, technique of stenting, number of stent, length of
tent, and so forth, because they are factors reflecting the
reatment modalities rather than the anticipated prognosis
f the treatment. Parameters describing lesion characteris-
ics were also excluded because they were incorporated in
he SYNTAX score: for example, Medina classification,
hronic total occlusion, American College of Cardiology/
merican Heart Association lesion classification (45).
Long-term outcomes after PCI in the LM population are
imited. Park et al. (46) reported the 3-year safety composite
ate (death, Q-wave MI, or stroke) of 9.7% with TVR rate
f 12.6%. Vaquerizo et al. (12) demonstrated the device-
riented composite end point at 2 years of 12.6% after
CLMA stenting with paclitaxel-eluting stents in 291
atients from multicenter registry. In these registries, the
atients with acute MI or cardiogenic shock were excluded;
hereas in our registry, such patients were included and had
negative impact on clinical outcomes. Also, frequent use of
ntravascular ultrasound might contribute the relatively
ower mortality in the Korean registry than in our European
egistry (46). In one of largest “all-comer” DELFT (Drug-
luting Stent for Left Main) registries exclusively using
ES in ULMCA with 3-year complete follow-up, Meliga
t al. (15) demonstrated 3-year MACE rate (a composite of
ardiac mortality, MI, and TVR) of 26.5%, cardiac mortal-
ty of 9.2%, and TVR of 14.2%. If the same composite
efinition were applied to the present study, the 3-year
ACE rate in our study (26.0%) would be similar to the
ELFT registry (26.5%). Wood et al. (47) reported a
ong-term outcome of 100 patients with high surgical risk
fter PCI. All-cause mortality at 28 months was 21%;
vent-free survival was around 65% at 27 months (47).
In the current study, the baseline patient demographics
re comparable between the current and the historical
ohorts. Although the anatomical complexity reflected by
YNTAX score was comparable between the 2 cohorts (the
urrent cohort 39.4 vs. the historical control 36.8, p 0.96),
he cohort with DES was more aggressively treated than the aistorical cohort with BMS, as indicated by a higher
ncidence of bifurcation stenting (48% vs. 57%, p  0.04),
y a larger number of stents implanted (2.85  0.47 vs.
.08  0.37), and by on average a longer stented length
42.4  28.4 mm vs. 59.9  40.4 mm).
The source of our concerns is the increase of the patient-
riented composite in the DES group between 2 and 4
ears, which was significantly higher than in the historical
ohort of BMS, and the long-term safety of DES in the
reatment of patients with ULMCA remains an unanswered
uestion. One possible explanation for unfavorable
ollow-up could be the occurrence of occult stent thrombo-
is. Occlusion of the LM trunk with thrombus is likely to be
ethal. Thus, patients can present with sudden and/or
ut-of-hospital death rather than with angiographically
roven stent thrombosis. The very late stent thrombosis
resenting with out-of-hospital death, however, can be
ndiagnosed and under-reported. The cause of death was
btained from the civil registry, and it is up to the general
ractitioners to classify the cause of mortality according to
nternational Classification of Diseases and Related Health
roblems-10th Revision unless the patient passed away in
he hospital. Therefore, no attempt was made to impute
eath to possible or probable stent thrombosis.
In the large multicenter registry (n  731) by Chieffo et
l. (17), the cumulative incidence of stent thrombosis at 29.5
onths after LM stenting was reported to be 0.95% for
efinite stent thrombosis and 2.7% for possible stent throm-
osis. In DELFT registry (15) (n  358) at 3-year
ollow-up, the incidence of definite, probable, and possible
tent thrombosis were 0.6%, 1.1%, and 4.4%. In ISAR-
EFT MAIN (Intracoronary Stenting and Angiographic
esults: Drug-Eluting Stents for Unprotected Coronary
eft Main Lesions) trial (48) (n  607), the 2-year rate of
efinite or probable stent thrombosis was about 0.5% to
.0%. In a series of high surgical risk patients, Wood et al. (47)
eported a 5% possible stent thrombosis presenting as
udden death. Taking into account the late increase in
ortality shown in our study, follow-up extending beyond 3
ears is warranted for patients receiving DES in the setting
f ULMCA.
The bifurcation angle has been shown to relate not only
o the difficulty level of the procedure but is also associated
ith intermediate outcomes. Dzavik et al. (19) reported that
bifurcation angle 50 was an independent predictor of
ACE at 1 year after bifurcation crush stenting in 133
atients. In 132 patients receiving Cypher stents in bifur-
ations excluding LM lesions, Adriaenssens et al. (49)
eported that increasing bifurcation angles is an indepen-
ent predictor of binary restenosis (HR: 1.53 [95% CI: 1.04
o 2.23] per 10° increase in angulation) after culotte stent-
ng. The worse outcomes in high-angulated bifurcation
esions might be the result of the adjacent presence of low
nd high shear stress found in bifurcation lesions. High
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593hear stress possibly stimulates platelet activation and ag-
regation, and low shear stress might enhance deposition of
latelets. This mechanism can be potentially exaggerated in
igher bifurcation angles. Furthermore, when bifurcation
tenting is performed in high-angle lesions, the stent will
ikely not appose against the wall of bifurcation (50),
specially in the ostium of the left circumflex artery (20). In
he present study, however, we observed that the bifurcation
ngle between the left anterior descending and left circum-
ex arteries was not an independent predictor for adverse
vents, although there is a weak statistical association with
-year composite end points in the univariate analysis (HR:
.99 [95% CI: 0.93 to 4.26], p  0.07).
tudy limitations. This study has several limitations. This is
single center, observational study that included a modest
umber of patients. The results of this landmark analysis
reporting a higher event rate in patients treated with DES
ompared with BMS after 2 years) would need to be
onfirmed in a larger study. In addition, the low 1-year
ortality rate compelled us to include only 2 or 3 indepen-
ent variables in the Cox regression model, resulting in
verfitting of the model. Confounding factors, such as
rocedural variables, might have been overlooked. Although
aseline characteristics were similar in the historical BMS
nd current DES groups, some procedural variables were in
act different and as a result might have influenced
utcomes.
onclusions
ur study reports a late increase in adverse events up to 4
ears, which warrants careful follow-up of the patient
eceiving DES in the LM trunk. The SYNTAX score and
uroSCORE can be considered important components of
isk stratification.
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